Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation ...(ur expectations or in events conditions ...),Health

Date:11/6/2009

ur expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Use of non-GAAP Financial Information

A reconciliation of the Company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the Company's use of these non-GAAP measures, is included in the exhibits attached to this press release.

                           BOSTON SCIENTIFIC CORPORATION
        NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS
                                    (Unaudited)


                                      Three Months Ended September 30, 2009
                                      -------------------------------------
                                         Previously
                                          Reported            As Updated
                                         -----------          ----------
                                               Impact                 Impact
                                                 per        Net         per
    In millions, except per share      Net     diluted     (loss)     diluted
     data                             income    share      income      share
    -----------------------------     ------    -----      ------      -----
    GAAP results                       $200      $0.13       $(94)    $(0.06)
    Non-GAAP adjustments:
        Restructuring-related
         charges                         21       0.01         21       0.01
        Litigation-related net
         (credits) charges              (37)     (0.02)       257       0.17*
        Amortization expense            107       0.07        107       0.07*
                                        ---       ---- 
'/>"/>
SOURCE  Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death